An Experimental Single-Time Treatment Slashed Cholesterol for a Year
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"An Experimental Single-Time Treatment Slashed Cholesterol for a Year" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Investing.com Canada, GuruFocus, Cleveland Clinic Newsroom and KCRA. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 77d ago.
Quick answers
Why is "An Experimental Single-Time Treatment Slashed Cholesterol for a Year" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (9)
- #ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy Endpoints News · 77d ago
- CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 Yahoo Finance · 77d ago
- Snipping a gene to reduce bad cholesterol for life looks possible CNN · 77d ago
- A One-Time Treatment for High Cholesterol Shows Promising Results Time Magazine · 77d ago
- CRISPR Therapeutics reports one-year data for gene therapy CTX310 By Investing.com Investing.com Canada · 77d ago
- CRSP Shares React to Promising CTX310 Trial Data Amid High Price-to-Sales Valuation GuruFocus · 77d ago
- Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely and Continuously Lower Cholesterol and Triglycerides After One Year Cleveland Clinic Newsroom · 77d ago
- With the snip of a gene, scientists hope to erase high cholesterol for life KCRA · 77d ago
- An Experimental Single-Time Treatment Slashed Cholesterol for a Year The New York Times · 77d ago
Topics
Related trends
Two-drug therapy reduces heart artery plaque more than statins alone
New clinical study findings reveal conflicting evidence regarding the efficacy of combining statins with ezetimibe.
Why heart attacks can still happen even when bad cholesterol is low
New medical coverage explores why heart attacks can still occur in adults who maintain normal, low levels of bad cholesterol.
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.
What Eating Eggs Every Day Does to Your Body
Health experts and dietitians are analyzing the impact of daily egg consumption on the body, specifically debating the benefits of whole eggs versus egg whites.
Protein clues may help explain heart disease risk that persists despite lower LDL cholesterol
New research suggests specific protein patterns may help explain persistent heart disease risk despite lower LDL cholesterol.